Alemtuzumab as a Successful Antirejection Therapy: Experience in a Pediatric Renal Transplant Patient

KURT ŞÜKÜR E. D., ÖZÇAKAR Z. B., KEVEN K., ÇAKAR N., Yalçınkaya F.

Experimental and Clinical Transplantation, cilt.21, sa.10, ss.848-850, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 10
  • Basım Tarihi: 2023
  • Doi Numarası: 10.6002/ect.2018.0203
  • Dergi Adı: Experimental and Clinical Transplantation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.848-850
  • Anahtar Kelimeler: Children, Kidney transplantation, Monoclonal antibody, Resistant rejection
  • Ankara Üniversitesi Adresli: Evet

Özet

Alemtuzumab is a monoclonal antibody against CD52 that is being increasingly used in renal transplantation as a lymphocyte-depleting agent. Data on alemtuzumab use in resistant rejection episodes are scarce, especially in children. Here, we present a 14-year-old renal transplant patient with acute cellular and humoral rejection who was treated with pulse steroids, plasmapheresis, and intravenous immunoglobulin with no success. He had 2 previous rejection episodes that were treated with antithymocyte globulin. In the third episode, alemtuzumab was given as a rescue therapy, and the patient benefited from the treatment. No complications were observed. Alemtuzumab can be a treatment option in pediatric patients with refractory rejection episodes.